jRCT2031240500招募中不适用
A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of the oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors (SYLVER)
GlaxoSmithKline K.K.0 个研究点目标入组 7 人开始时间: 2025年1月29日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Parts 1, 2, and 3 inclusion criteria:
- •Has a histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor
- •Has a known dMMR/MSI-H status as determined by a certified local laboratory at the time of Pre-screening or has an unknown Mismatch repair (MMR)/ Microsatellite Instability (MSI) status at the time of Pre-screening and MMR/MSI status will be determined by central reference laboratory
- •Provides an archival or fresh (preferred) formalin fixed, paraffin embedded (FFPE) sample
- •Intends to receive GSK4418959 (alone or in combination with PD-1 inhibitor, as determined between Investigator and sponsor) as next line of treatment
- •Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Is expected to have a minimum of 3 months life expectancy
- •Has adequate organ function, as defined in the protocol
- •Parts 1 and 3 inclusion criteria:
- •Has histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor and has exhausted all standard of care treatment options
- •Part 2 inclusion criteria:
- •Has histologically diagnosed advanced (unresectable, metastatic or recurrent) Colorectal cancer (CRC) or Endometrial cancer (EC)
- •Has received at least 1 but no more than 3 lines of systemic anticancer therapy for their advanced (unresectable, metastatic or recurrent) disease including at least one line of Immune checkpoint inhibitors (ICI) therapy
- •Has measurable disease (i.e., at least 1 target lesion) during the Screening period per RECIST 1.1, as determined by the investigator
排除标准
- •Parts 1, 2, and 3 exclusion criteria:
- •Has not recovered (i.e., to Grade <-1 or to baseline) from prior anticancer therapy-induced AEs
- •Has received prior treatment with a WRN inhibitor
- •Is unable to swallow and retain orally administered study treatment
- •Has symptomatic uncontrolled brain or leptomeningeal metastases
- •Has a known additional malignancy that progressed or required active treatment within the last 2 years because reoccurrence of another malignancy would confound interpretation by RECIST 1.1 criteria. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cancer that is considered to be low risk for progression by the investigator
- •Has any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs
- •Has severe liver fibrosis
- •Has cirrhosis or current unstable liver or biliary disease
- •Has known hypersensitivity to any of the study interventions or any of their excipients
- •Has known WRN syndrome
- •Has an active autoimmune disease that has required systemic treatment in the past 2 years
- •Part 3 exclusion criteria:
- •Has experienced any of the following with prior immunotherapy: any immune mediated adverse events (imAE) of Grade >-3, immune-related severe neurologic events of any grade, exfoliative dermatitis of any grade (Stevens-Johnson Syndrome, toxic epidermal necrolysis, or Drug rash with eosinophilia and systemic signs syndrome [DRESS] syndrome), or myocarditis of any grade. Non-clinically significant laboratory abnormalities are not exclusionary
- •Has any history of interstitial lung disease or pneumonitis
研究者
相似试验
招募中
不适用
Preliminary study for examining the safety and efficacy of fecal transplantation therapy in refractory intestinal diseasesrefractory intestinal diseasesJPRN-UMIN000026363agoya University20
招募中
1 期
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.Hematologic MalignanciesNCT06756451Nanjing RegeneCore Biotech Co., Ltd.71
进行中（未招募）
4 期
To assess safety and effectiveness of Rivaroxaban(Xarelto)in managing coronary and or symptomatic peripheral artery disease in Indian PatientsCTRI/2022/01/039597Bayer Zydus Pharma Pvt Ltd
进行中（未招募）
1 期
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid TumorsAdvanced Solid TumorNCT05007782Gilead Sciences304
撤回
1 期
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.PART 3.Infection - Other infectious diseasesMalariaACTRN12613000533796CPR Pharma Services24